Figure 5. FDA and EMA recommendations for use of NOACs in patients with hepatic impairment .

ALT: alanine transaminase; AST: aspartate transaminase; EMA: European Medical Agency; FDA: Food and Drug Administration; NOACs: novel oral anticoagulants; ULN: upper limit of normal

The figure is adapted from Qamar et al. (2018) [41].